Primary Care Clinics in Foxboro, MA Accepting Medicare
7 Primary Care Clinics found. Showing 1 - 7
 Hua Zhang Md Llc Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 113 Washington St, Foxboro, MA 02035 Phone: 508-543-1553 Fax: 508-543-1488 |
Foxboro Family Practice, Pc Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 56 Leonard St, Suite 7, Foxboro, MA 02035 Phone: 508-543-2206 Fax: 508-543-2231 |
Zhang Medical Associates, Pllc Internal Medicine Medicare: Medicare Enrolled Practice Location: 15 Payson Rd Ste 2, Foxboro, MA 02035 Phone: 617-838-5762 |
Foxboro Center For Women's & Family Health Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 18 Washington St, Foxboro, MA 02035 Phone: 508-698-5350 Fax: 508-698-5373 |
Caritas Physical Therapy At Foxboro Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 56 Leonard St, Foxboro, MA 02035 Phone: 671-562-5482 Fax: 617-562-5415 |
Ahmed Basheer, M.d.,p.c. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 56 Leonard St, Suite 7, Foxboro, MA 02035 Phone: 508-543-3633 Fax: 508-543-1154 |
Caritas Foxboro Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 70 Walnut St, Foxboro, MA 02035 Phone: 617-562-5482 Fax: 617-562-5415 |
News Archive
Dacomitinib treatment for lung cancer increases overall survival but has more side effects
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations.
New blood pressure drug Micardis (Telmisartan) good at reducing deaths from heart attacks
An international team of researchers have found that a new blood pressure medication is as effective in reducing cardiovascular death, with fewer side effects than the current treatments offered.
Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering
Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.
U of M Udall Center receives $11.3 million grant to continue research on deep brain stimulation for Parkinson's disease
The Udall Center at the University of Minnesota Medical School was awarded a new $11.3 million grant from the National Institute for Neurological Disorders and Stroke to continue its work in deep brain stimulation (DBS) for Parkinson's disease.
› Verified 8 days ago